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Action potentials reﬂect the concerted activity of all electrogenic constituents in the plasma
membrane during the excitation of a cell. Therefore, the action potential is an integrated
read out and a promising parameter to detect electrophysiological failures or modiﬁcations
thereof in diagnosis as well as in drug screens. Cellular action potentials can be recorded
by optical approaches. To fulﬁll the pre-requirements to scale up for, e.g., pharmacological
screens the following preparatory work has to be provided: (i) model cells under investi-
gation need to represent target cells in the best possible manner; (ii) optical sensors that
can be either small molecule dyes or genetically encoded potential probes need to provide
a reliable read out with minimal interaction with the naive behavior of the cells and (iii)
devices need to be capable to stimulate the cells, read out the signals with the appropriate
speed as well as provide the capacity for a sufﬁcient throughput. Here we discuss several
scenarios for all three categories in the ﬁeld of cardiac physiology and pharmacology and
provide a perspective to use the power of light in screening cardiac action potentials.
Keywords: cardiac action potentials, membrane potential dyes, genetically encoded membrane potential sensors,
human cardiac myocytes, optical screens
INTRODUCTION
Pharmacological screening of ion channels is traditionally per-
formed by the patch-clamp technique, related tools, and their
automated incarnations or indirect ﬂuorescence as well as lumi-
nescence based end-point measurements. There are good reasons
why the patch-clamp technique is the gold standard in investigat-
ing ion channels, such as the possibility to isolate speciﬁc currents
or to characterize single channels. However, there are scientiﬁc
questions, pharmacological approaches, or medical requirements,
when the concert of electrogenic membrane transport entities
are of particular interest. Such a situation is, e.g., the measure-
ment of action potentials for cardiac safety issues. The action
potential duration can be regarded as a cellular equivalent of the
QT-Interval in electrocardiograms (Arrigoni and Crivori, 2007).
Since the investigation of action potential considers all electro-
genic elements and is thus not limited to a single entity, e.g., hERG
channels, the screening of action potentials bears a conceptional
advantage. Action potentials can be measured optically for almost
four decades (Salzberg et al., 1973). Beside the measurement of
action potentials in isolated primary cells, optical methods can
follow cellular action potentials and their interplay in tissue slices
and entire organs (e.g., Jin et al., 2002; Lee et al., 2011). Here we
describe recent advances and promising perspectives in screening
cardiac action potentials.
CELLULAR SYSTEMS
When it comes to cellular systems for cardiac safety screens we
ﬁnd an inherent conﬂict; on one hand cells should be as close
as possible to human situation and on the other hand simplic-
ity of operation. Since optical approaches operate contact free,
they bear the potential to screen even very fragile cells like human
atrial myocytes as depicted in Figure 1A. Human cardiomyocytes,
either atrial myocytes from appendages after surgery involving
heart–lung machines (Kaestner and Lipp, 2007) or ventricular
myocytes taken from biopsies, facilitate screening drugs for per-
sonalizedmedication.However, for pharmacological safety screens
one would need to switch to animal models: for adult ventricu-
lar myocytes we recently described a reliable isolation procedure
(Kaestner et al., 2009) as well as optimized culture conditions
(Viero et al., 2008; Hammer et al., 2010). Furthermore we com-
pared neonatal and adult cardiomyocytes in a basic pharmacolog-
ical proﬁling (Tian et al., 2011), showing that neonatal cells do
not reﬂect the adult situation at all. The present guidelines of FDA
and EMEA for cardiac safety screens (Food and Drug Administra-
tion,HHS, 2005) explicitly exclude rodents for such investigations
because adult animals almost completely lack hERG expression.
However, neonatal cardiomyocytes express hERG (Kaestner et al.,
2011a; Tian et al., 2011) and therefore the guidelines may need a
revision. Furthermore, it might have to be considered that dur-
ing aging and many cardiac diseases re-expression of fetal and/or
neonatal genes might change this situation. Very promising are
the ongoing developments and reﬁnements to differentiate cardiac
myocytes from embryonic or pluripotent stem cells (e.g., Ketten-
hofen and Bohlen, 2008) and (Moretti et al., 2010), respectively.
The years to come will show to what extend stem cell derived
cardiomyocytes will enter cardiac safety screens – the potential is
enormous.
OPTICAL SENSORS
Since action potentials in cardiomyocytes are convolved by cellu-
lar contraction artifacts optical read out need to be performed in
a quantitative manner, e.g., based on ratiometric or ﬂuorescence
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FIGURE 1 | (A) Depicts isolated human atrial myocytes loaded with the
membrane potential dye di-8-ANEPPS. Image (a) displays a max. intensity
projection of a confocal z-stack of two atrial myocytes, while image (b)
depicts a cut open 3D-reconstruction of the same cells. The cells are virtually
cut open along the lines c,d in image (b) and the view into the cells from that
position is displayed in images (c,d), respectively. (B) Illustrates that the
patch-clamp technique (black line) and the optical sensor (red line) measure
exactly the same potential. Even the stimulation artifact of the patch-clamp
technique to induce an action potential translates into the optical signal (black
arrow). (C) Shows that the di-8-ANEPPS, when applied at a concentration of
5μM for 7min, does not disturb the naive action potential. (a) Displays action
potentials recorded by patch-clamp before and after the di-8-ANEPPS staining
procedure. (b) Depicts a statistical analysis of action potential duration in cells
measured by the patch-clamp technique (n =94) and measured by the optical
di-8-ANEPPS read out (n =214). (B,C) are reproduced fromTian et al. (2011)
with friendly permission of S. Karger AG (Basel, Switzerland).
lifetime approaches. Alternatively, contractions can be suppressed,
but this is problematic since compounds such as BDM or cytocha-
lasin D prolong the action potential in the required concentrations
(discussed in Tian et al., 2011). Blebbistatin is a more promis-
ing drug, but is easily photoconverted (Tian et al., 2011). For
quantitative read-out ﬂuorescence lifetime imaging is inherently
too slow (Kaestner et al., 2011b). Therefore we regard ratio-
metric approaches as the method of choice. Small molecule
dyes such as di-4-ANEPPS or di-8-ANEPPS can be used in an
excitation or emission ratiometric manner. Although, with the
availability of diode based light sources switching times between
excitation wavelengths can be fairly short (Lee et al., 2011),
emission ratiometric scenarios generate both channels simulta-
neously allowing at least two times the acquisition speed. For
di-8-ANEPPS it was shown that (a) it resembles action poten-
tials from current clamp recordings (e.g., Figure 1B) and (b)
the naive action potential is not inﬂuenced by the probe, if
applied appropriately (Figure 1C; Tian et al., 2011). A promis-
ing development is a novel dye, called di-4-ANBDQPQ (Matiukas
et al., 2007; Lee et al., 2011), that shows bathochromely shifted
spectra and therefore may be used in the presence of GFP,
that is often expressed, e.g., as cardiac marker in stem cell
environments.
Yet another approach to potential sensitive sensors are geneti-
cally encoded potential probes. We published a recent review with
particular emphasize on their application in cardiac myocytes
(Kaestner et al., 2011b). One of the most promising candidates,
the FRET based “Mermaid,” is introduced in Figure 2. The use of
novel ﬂuorescent proteins (Figure 2A) requires unusual detection
channels when compared to the “classical” FRET pair CFP/YFP
(Figure 2B). Especially since the mKusabira orangeκ is prawn
to rapid bleaching it is not easy to get the best out of Mermaid
(Atsushi Miyawaki and Hidekatzu Tsutsui, personal communica-
tion). Since there have been conﬂicting reports about the amino
acid sequence of the linker in Mermaid (Tsutsui et al., 2008;Mutoh
et al., 2009), we provide the sequence of the construct (Figure 2C)
that was used in our previous studies (Kaestner et al., 2011a;
Tian et al., 2011) as well as in Figure 2D. However, genetically
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FIGURE 2 | (A) Is a schematic illustration of the FRET based sensor Mermaid
containing two coral derived ﬂuorescence proteins, wheras the voltage
sensor containing a phosphatase of the sea squirt Ciona intestinalis, provides
the base for the conformational change. The spectral properties of these
ﬂuorescent proteins are given in (B) (mUmi-Kinoko green lines and mKuabira
orangeκ orange lines; excitation spectra dashed lines and ﬂuorescence
spectra solid lines). (A,B) are reprinted by permission from Macmillan
Publishers Ltd: Nature Methods (Tsutsui et al., 2008), copyright (2008). Since
there have been conﬂicting reports concerning the linker sequences of
Mermaid (Tsutsui et al., 2008; Mutoh et al., 2009), in (C) we provide the
linker sequence of the construct used for our investigations [cp. (D)].
(D) Depicts action potential recordings from viral transduced Mermaid in
isolated ventricular myocytes. (a,b) Are traces of the ﬂuorescence intensity of
the two spectral channels, while (Dc) presents the ratio of (a,b). (D) Is a
reprint fromTian et al. (2011) with friendly permission of S. Karger AG (Basel,
Switzerland).
encoded potential sensors bear a potential for further improve-
ments, especially with respect to their kinetic properties (Kaestner
et al., 2011b).
DEVICES
To perform optical screens there are several requirements for the
hardware, comprising three major components: (i) cell substrate
and cavity that meet the conditions for optical screens, (ii) a
microscope for imaging and (iii) a robotic system that handles
the workﬂow:
(i) A suitable substrate with oleophobic properties compati-
ble with oil immersion objectives on the outside and elastic
coating to mimic extracellular matrix on the inside was intro-
duced recently (Muller et al., 2010). This was implemented in
24-well plates, as shown in Figure 3A, but would need further
integration into 96 well plates and beyond. For electrical ﬁeld
stimulation of the cells this particular model used carbon
electrodes incorporated into the lid. This method has the dis-
advantage of producing unwanted electrolytic by-products
that need to be taken care of, e.g., by more frequent change
of the medium. Alternative concepts include cell stimula-
tion by electromagnetic ﬁelds with an appropriate coil. Since
such a coil would need proximity to the cells there are spatial
conﬂicts with the objective. Another promising alternative
to excite cardiomyocytes is the optogenetic manipulation by
the expression of channelrhodopsin, a light-activated cation
channel, that can induce action potentials (Bruegmann et al.,
2010).
(ii) As mentioned above fast read out of membrane poten-
tials requires emission ratiometric approaches that in the
past were only performed with photometric techniques (e.g.,
Hardy et al., 2009; Kaestner et al., 2011a,b). To increase the
throughput many cells need to be measured simultaneously.
Suchproperties are offered by systems employing array detec-
tors. Figure 3B depicts a design of a microscope with an
integrated image splitter projecting two spectral channels on
one camera chip. Recent developments of CMOS camera
chips (Coates et al., 2009; Figure 3Ca) provide a technol-
ogy unifying high acquisition speed (Figure 3Bb) and good
quantum efﬁciency (Figure 3Bc). Within the near future the
latter parameter will improve even further since back thinned
scientiﬁc CMOS chips will become available.
www.frontiersin.org July 2011 | Volume 2 | Article 42 | 3
Kaestner and Lipp Screening action potentials: the power of light
FIGURE 3 | Hardware enabling optical action potential screens. (A)
Depicts a 24-well plate allowing an electrical ﬁeld stimulation of cardiac
myocytes under the application of high numerical aperture oil immersion
objectives. For a detailed description refer to Muller et al. (2010)). (B) Shows a
design of a prototype microscope, which is representative for a new
generation of microscopes allowing a precise screen of standard multi-well
plates and be able to detect two emission channels simultaneously on array
detectors like CCD or CMOS based cameras. (B) Is a courtesy from Prof.
Rainer Uhl (TILL I.D. GmbH, Gräfelﬁng, Germany). (C) Shows the state of the
art scientiﬁc CMOS sensor (a) and key speciﬁcations of that sensor, what are
frame rates in the range of 1 kHz (b) and a quantum efﬁciency of 60% around
550nm (c). (D) Is modiﬁed from Coates et al. (2009).
(iii) To perform screens an automated plate and liquid handling,
electrical stimulation (see above), and a complex microscopy
protocol are compulsory. Although each of the elements is
readily available on its own, a device combining the necessary
hardware and an advanced software allowing online analysis
and feedback into the acquisition procedure remains to be
developed.
CONCLUSION
Beside the conceptional advantages of screening action poten-
tials as outlined in the introduction, optical screens have a
minimal requirement for the cellular system, since cells do
not need to be mechanically manipulated. Therefore it is a
very ﬂexible screening approach and eventually the only one
that can be applied to intact adult cardiomyocytes, in addi-
tion to model cells and stem cell derived cardiomyocytes. Action
potential screening can be combined with other optical mea-
surements, such as those employing GFP for identifying stem
cell derived cardiomyocytes (see above) or for imaging calcium
(Lee et al., 2011). Additionally, optical screening that takes advan-
tage of genetically encoded potential sensors allows experimental
regimes in which cells can be revisited, even after a couple of
days. Taken together, the possibilities of optical action potential
screening may enable novel ﬁelds of application beyond cardiac
safety.
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